Persistent Neutrophil Infiltration and Unique Ocular Surface Microbiome Typify Dupilumab-Associated Conjunctivitis in Patients with Atopic Dermatitis

VijayKumar Patra; Nora Woltsche; Urban Cerpes; Danijela Bokanovic; Maria Repelnig; Aaroh Joshi; Isabella Perchthaler; Manuela Fischl; Marc Vocanson; Natalie Bordag; Marija Durdevic; Johannes Woltsche; Franz Quehenberger; Franz Legat; Andreas Wedrich; Jutta Horwath-Winter; Peter Wolf

doi:10.1016/j.xops.2023.100340

Persistent Neutrophil Infiltration and Unique Ocular Surface Microbiome Typify Dupilumab-Associated Conjunctivitis in Patients with Atopic Dermatitis

Ophthalmol Sci. 2023 May 29;4(1):100340. doi: 10.1016/j.xops.2023.100340. eCollection 2024 Jan-Feb.

Authors

VijayKumar Patra^{1

2}, Nora Woltsche³, Urban Cerpes¹, Danijela Bokanovic¹, Maria Repelnig¹, Aaroh Joshi¹, Isabella Perchthaler¹, Manuela Fischl³, Marc Vocanson², Natalie Bordag¹, Marija Durdevic^{4

5

6}, Johannes Woltsche¹, Franz Quehenberger¹, Franz Legat¹, Andreas Wedrich³, Jutta Horwath-Winter³, Peter Wolf^{1

7}

Affiliations

¹ Department of Dermatology, Medical University of Graz, Graz, Austria.
² Centre International de Recherche en Infectiologie, Institut National de la Santé et de la Recherche Médicale, U1111, Université Claude Bernard Lyon 1, Centre National de la Recherche Scientifique, UMR5308, École Normale Supérieure de Lyon, Université de Lyon, Lyon, France.
³ Department of Ophthalmology, Medical University of Graz, Graz, Austria.
⁴ Computational Bioanalytics, Center for Medical Research, Medical University of Graz, Graz, Austria.
⁵ Institute of Pathology, Medical University of Graz, Graz, Austria.
⁶ Theodor Escherich Laboratory for Medical Microbiome Research, Medical University of Graz, Graz, Austria.
⁷ BioTechMed Graz, Graz, Austria.

Abstract

Objective: To elucidate the pathogenesis of dupilumab (Dupixent®)-associated ocular surface disease (DAOSD).

Design: Prospective single-center cohort study.

Subjects: Twenty patients with moderate-to-severe atopic dermatitis (AD) who received dupilumab and 10 age- and sex-matched healthy controls were enrolled in the study.

Methods: The study cohort underwent a thorough slit-lamp and entire-body dermatologic examination. Conjunctival swabs and smears were collected at baseline, 4 and 16 weeks after treatment initiation, and during the conjunctivitis episode. To analyse the ocular surface microbiome, 16S ribosomal RNA sequencing was performed, smears were hematoxylin and eosin stained, and serum cytokines were measured by using a multiplex immunobead assay.

Main outcome measures: Composition of ocular surface microbiome and cellular component as well as serum cytokine levels.

Results: Six of the 20 patients with AD developed DAOSD after dupilumab initiation; these patients responded after a delay to treatment as quantified by Eczema Area and Severity Index and Investigator's Global Assessment score. Conjunctival smears showed massive neutrophilic infiltration and serum analysis revealed increased systemic levels of neutrophil-priming proinflammatory cytokines, in particular interleukin-1β and tumor necrosis factor α, in patients with DAOSD compared with those without it. The ocular surface microbiome of patients with DAOSD was characterized by a diverse and persistent microbial colonization, particularly by Acetobacter aceti. In contrast, microbial diversity decreased in patients with AD without DAOSD after the initiation of dupilumab treatment, especially the abundance of Staphylococcus aureus. In vitro experiments substantiated the potential role of the microbiome, showing increased growth of A. aceti and decreased growth of S. aureus in presence of dupilumab.

Conclusions: Persistent neutrophilic infiltration and a unique microbial landscape on the ocular surface associated with elevated levels of systemic proinflammatory cytokines typify DAOSD.

Financial disclosures: Proprietary or commercial disclosure may be found after the references.

Keywords: Atopic dermatitis; Cytokines; Dupilumab; Microbiome; Neutrophils.